MX376029B - Compuestos de isoindol. - Google Patents

Compuestos de isoindol.

Info

Publication number
MX376029B
MX376029B MX2018007296A MX2018007296A MX376029B MX 376029 B MX376029 B MX 376029B MX 2018007296 A MX2018007296 A MX 2018007296A MX 2018007296 A MX2018007296 A MX 2018007296A MX 376029 B MX376029 B MX 376029B
Authority
MX
Mexico
Prior art keywords
compound
isoindole compounds
isoindole
compounds
rorî3t
Prior art date
Application number
MX2018007296A
Other languages
English (en)
Other versions
MX2018007296A (es
Inventor
Frank Narjes
Roine Ingemar Olsson
Sarah LEVER
Berg Stefan Von
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018007296A publication Critical patent/MX2018007296A/es
Publication of MX376029B publication Critical patent/MX376029B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente memoria descriptiva proporciona un compuesto de fórmula (I): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo; un proceso para preparar tal compuesto; y al uso de tal compuesto en el tratamiento de una patología mediada por ROR? y/o ROR?t.
MX2018007296A 2015-12-15 2016-12-14 Compuestos de isoindol. MX376029B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267391P 2015-12-15 2015-12-15
PCT/EP2016/080885 WO2017102784A1 (en) 2015-12-15 2016-12-14 Isoindole compounds

Publications (2)

Publication Number Publication Date
MX2018007296A MX2018007296A (es) 2019-01-10
MX376029B true MX376029B (es) 2025-03-07

Family

ID=57708552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007296A MX376029B (es) 2015-12-15 2016-12-14 Compuestos de isoindol.

Country Status (27)

Country Link
US (4) US10011566B2 (es)
EP (1) EP3390396B1 (es)
JP (1) JP6448867B2 (es)
KR (1) KR101947976B1 (es)
CN (1) CN109071516B (es)
AR (1) AR107054A1 (es)
AU (1) AU2016374294B2 (es)
BR (1) BR112018011851A2 (es)
CA (1) CA3007893A1 (es)
CL (1) CL2018001573A1 (es)
CO (1) CO2018005983A2 (es)
CR (1) CR20180328A (es)
DO (1) DOP2018000148A (es)
EA (1) EA034514B1 (es)
ES (1) ES2927631T3 (es)
IL (1) IL259818B (es)
MX (1) MX376029B (es)
MY (1) MY196276A (es)
NI (1) NI201800071A (es)
PE (1) PE20181319A1 (es)
PH (1) PH12018501237A1 (es)
SG (1) SG11201804587QA (es)
SV (1) SV2018005713A (es)
TN (1) TN2018000188A1 (es)
TW (1) TWI728017B (es)
WO (1) WO2017102784A1 (es)
ZA (1) ZA201804618B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI728017B (zh) 2015-12-15 2021-05-21 瑞典商阿斯特捷利康公司 異吲哚化合物、包含其之醫藥組成物及其用途
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
WO2020035557A1 (en) 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
WO2020035556A1 (en) 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
CA3178650A1 (en) * 2020-05-15 2021-11-18 Yaobang CHENG Aniline compound used as ror.gamma. regulator
TW202146389A (zh) * 2020-05-15 2021-12-16 大陸商上海輝启生物醫藥科技有限公司 可用作RORγ調節劑的聯芳基類化合物
KR102422891B1 (ko) 2022-01-26 2022-07-20 (주)셀시스템 Ai기반 우선순위 제어기능을 구비한 일체형 태양광 온수 및 배터리 충전장치 및 이를 이용한 충전 방법
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
JP2000504014A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
KR20010041346A (ko) 1998-02-25 2001-05-15 브루스 엠. 에이센, 토마스 제이 데스로저 포스포리파제 ａ2 억제제
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
JP2004500332A (ja) 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
CA2408486A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
JP2004515494A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
US7385063B2 (en) 2001-01-26 2008-06-10 Chugai Seiyaku Kabushiki Kaisha Method for preparing imidazole derivatives
WO2003041641A2 (en) 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20050171084A1 (en) 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
EP1501867A1 (en) 2002-04-29 2005-02-02 Novartis AG Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
WO2005009383A2 (en) 2003-07-22 2005-02-03 Glaxo Group Limited Methods of treatment with lxr agonists
US20060205819A1 (en) 2003-07-28 2006-09-14 Yukio Goto Methods of treatment inflammatory bowel with lxr agonists
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
TW200808723A (en) 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
CN101490002A (zh) * 2006-07-12 2009-07-22 阿斯利康(瑞典)有限公司 作为止痛剂的3-氧代异二氢吲哚-1-甲酰胺衍生物
TW200812962A (en) 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
RU2009114159A (ru) 2006-09-15 2010-10-20 Селджин Корпорейшн (Us) N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013100027A1 (ja) 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013159095A1 (en) 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
US9447069B2 (en) 2012-04-30 2016-09-20 Innov17 Llc ROR modulators and their uses
US9708268B2 (en) 2012-04-30 2017-07-18 Innov17 Llc ROR modulators and their uses
KR101936851B1 (ko) * 2012-07-16 2019-01-11 한국과학기술연구원 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
EP2991994B1 (en) 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ror-gamma
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
US9745267B2 (en) 2013-09-05 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
US9738600B2 (en) 2013-12-05 2017-08-22 Lead Pharma Cel Models Ip B.V. ROR gamma (RORγ) modulators
WO2015083130A1 (en) 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
SI3102576T1 (sl) 2014-02-03 2019-08-30 Vitae Pharmaceuticals, Llc Inhibitorji dihidropirolopiridina ROR-gama
WO2015129853A1 (ja) 2014-02-27 2015-09-03 東レ株式会社 環状アミン誘導体及びその医薬用途
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
LT3131902T (lt) 2014-04-14 2019-09-25 Boehringer Ingelheim International Gmbh Junginiai, kaip ror-gama moduliatoriai
EA201691491A1 (ru) 2014-04-16 2017-02-28 Гленмарк Фармасьютикалс С.А. Арильные и гетероарильные эфиры в качестве модуляторов ror-гамма
TN2016000567A1 (en) 2014-07-01 2018-04-04 Takeda Pharmaceuticals Co Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
LT3177612T (lt) 2014-08-04 2022-06-10 Nuevolution A/S Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US10865181B2 (en) 2014-11-05 2020-12-15 University Of Kansas Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016176399A1 (en) 2015-04-28 2016-11-03 Stc.Unm Compositions and methods for treatment of pulmonary hypertension
DK3294713T5 (da) 2015-05-15 2021-05-31 Aurigene Discovery Tech Ltd Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017010399A1 (ja) 2015-07-10 2017-01-19 塩野義製薬株式会社 ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3356366B1 (en) 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
TWI728017B (zh) 2015-12-15 2021-05-21 瑞典商阿斯特捷利康公司 異吲哚化合物、包含其之醫藥組成物及其用途

Also Published As

Publication number Publication date
AR107054A1 (es) 2018-03-14
US20190084934A1 (en) 2019-03-21
JP6448867B2 (ja) 2019-01-09
CN109071516B (zh) 2021-08-31
CL2018001573A1 (es) 2018-07-27
US11453644B1 (en) 2022-09-27
US10011566B2 (en) 2018-07-03
US20200181084A1 (en) 2020-06-11
EA034514B1 (ru) 2020-02-14
KR101947976B1 (ko) 2019-02-13
IL259818B (en) 2021-05-31
CN109071516A (zh) 2018-12-21
WO2017102784A9 (en) 2018-04-05
CO2018005983A2 (es) 2018-06-20
US10988445B2 (en) 2021-04-27
DOP2018000148A (es) 2018-07-15
BR112018011851A2 (pt) 2018-12-04
PH12018501237A1 (en) 2019-02-18
EP3390396B1 (en) 2022-07-06
TWI728017B (zh) 2021-05-21
ZA201804618B (en) 2020-09-30
EA201891342A1 (ru) 2019-01-31
PE20181319A1 (es) 2018-08-14
TW201738210A (zh) 2017-11-01
CA3007893A1 (en) 2017-06-22
WO2017102784A1 (en) 2017-06-22
NI201800071A (es) 2018-10-18
TN2018000188A1 (en) 2019-10-04
KR20180086269A (ko) 2018-07-30
US10526286B2 (en) 2020-01-07
CR20180328A (es) 2018-08-09
EP3390396A1 (en) 2018-10-24
IL259818A (en) 2018-07-31
ES2927631T3 (es) 2022-11-08
SG11201804587QA (en) 2018-06-28
SV2018005713A (es) 2018-08-08
AU2016374294B2 (en) 2019-06-27
AU2016374294A1 (en) 2018-07-19
MX2018007296A (es) 2019-01-10
JP2018537485A (ja) 2018-12-20
MY196276A (en) 2023-03-24
US20170166527A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
MX376029B (es) Compuestos de isoindol.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
IN2015DN01156A (es)
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
TW201613864A (en) Novel compounds
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12017500089B1 (en) Aldosterone synthase inhibitors
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
IN2014MU00916A (es)
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
PH12016501808A1 (en) Chemical compounds
IN2014CH01391A (es)

Legal Events

Date Code Title Description
FG Grant or registration